Summary
The product Exemestane 10 mg, manufactured by Unique Pharma, was independently tested to verify its authenticity and potency. The sample, identified by batch number GH65721K, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis identified the sample as containing Exemestane, with a measured content of 9.29 mg per pill, which is 7.1% below the labeled claim of 10 mg.
The testing process commenced on 01 August 2022, with the sample received on 09 August 2022, and the analysis completed on 12 August 2022. The report indicates that the sample was retested twice, suggesting thorough verification of the results. While the product meets general expectations, the slight underdosing highlights the importance of ongoing independent verification across different batches to ensure product consistency.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: Exemestane 10 mg
- Active Ingredient: Exemestane
- Batch Number: GH65721K
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #22606
- Testing Ordered: 01 August 2022
- Sample Received: 09 August 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 10 mg (as stated on the label)
- Measured Concentration: 9.29 mg
- Accuracy: 92.9% (7.1% below the label claim)
- Variance: -7.1%
Verification Details
- Verification URL: https://janoshik.com/tests/22606_7KRGRDMQNRXT
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This analysis confirms the presence of Exemestane, though at a slightly lower concentration than stated on the label. The sample was retested twice, providing further assurance of the results; however, since the testing was submitted and funded by the reseller Opitropin.EU, there is a possibility of selective batch sampling. Additional third-party testing across multiple batches is recommended to ensure consistent quality.
Conclusion
The analysis of Exemestane 10 mg confirms a measured concentration of 9.29 mg, indicating an underdose of 7.1%. While the deviation is relatively small, consistent independent verification is crucial to ensuring that future batches maintain accuracy in dosing. This report serves as an educational resource to promote harm reduction and informed decision-making.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it still provides useful insights when critically assessed alongside independent third-party results. Readers are encouraged to use this information responsibly.
